氨基酸腹膜透析液在腹膜透析中的应用
The Application of Amino Acid-Based Peritoneal Dialysis Solutions in Peritoneal Dialysis
DOI: 10.12677/acm.2026.161087, PDF,   
作者: 程雅琳：赣南医科大学第一临床医学院，江西 赣州；李小生*：赣南医科大学第一附属医院肾内科，江西 赣州
关键词: 腹膜透析；氨基酸腹膜透析液；营养不良；Peritoneal Dialysis； Amino Acid Peritoneal Dialysis Solution； Malnutrition
摘要: 慢性肾脏病患者逐年增多，终末期肾病需进行肾脏替代治疗以维持生命。其中腹膜透析(peritoneal dialysis, PD)是肾替代治疗的重要手段之一，其改善氮质血症、尿毒症中毒症状、保护残余肾功能等疗效已获得临床肯定。随着透析效能及患者远期预后的不断改善，原有一些不受重视的并发症(如营养不良等)在临床上备受关注，但是改善此类并发症的方法有限。然而随着氨基酸透析液的出现，PD患者合并的全身性营养不良得到了改善并取得了一定的临床经验。本文系统梳理了氨基酸腹膜透析液的作用机制，临床证据及争议，为优化腹膜透析治疗策略提供参考。
Abstract: The prevalence of chronic kidney disease (CKD) has been increasing annually, with end-stage renal disease (ESRD) requiring renal replacement therapy to sustain life. Among the available treatments, peritoneal dialysis (PD) serves as one of the most important modalities. Its efficacy in ameliorating azotemia, uremic symptoms, and preserving residual renal function has been well-established in clinical practice. As dialysis efficiency and long-term patient outcomes continue to improve, previously overlooked complications such as malnutrition have gained significant clinical attention. However, therapeutic options for managing these complications remain limited. The advent of amino acid-based peritoneal dialysis solutions has shown promise in addressing systemic malnutrition in PD patients, yielding positive clinical experience. This article systematically reviews the mechanism of action, clinical evidence, and ongoing controversies surrounding amino acid peritoneal dialysis solutions, aiming to provide references for optimizing peritoneal dialysis treatment strategies.
文章引用：程雅琳, 李小生. 氨基酸腹膜透析液在腹膜透析中的应用[J]. 临床医学进展, 2026, 16(1): 652-660. https://doi.org/10.12677/acm.2026.161087

参考文献

[1] Teitelbaum, I. (2021) Peritoneal Dialysis. New England Journal of Medicine, 385, 1786-1795. [Google Scholar] [CrossRef] [PubMed]
[2] 骆雅咏, 董哲毅, 林雯文, 等. 营养评估方法在慢性肾脏病患者中的应用研究进展[J]. 解放军医学杂志, 2024, 49(12): 1437-1443.
[3] 管运才. 多糖腹膜透析液的制备与质量研究[D]: [硕士学位论文]. 南京: 南京大学, 2016.
[4] Kiebalo, T., Holotka, J., Habura, I. and Pawlaczyk, K. (2020) Nutritional Status in Peritoneal Dialysis: Nutritional Guidelines, Adequacy and the Management of Malnutrition. Nutrients, 12, Article No. 1715. [Google Scholar] [CrossRef] [PubMed]
[5] Rippe, B. and Venturoli, D. (2007) Peritoneal Transport Kinetics with Amino Acid-Based and Glucose-Based Peritoneal Dialysis Solutions. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 27, 518-522. [Google Scholar] [CrossRef] 
[6] 王军, 贾忠辉, 俞雨生. 氨基酸腹膜透析液在腹膜透析营养不良患者中的应用前景[J]. 医学研究生学报, 2004(6): 554-557.
[7] Faller, B., Aparicio, M., Faict, D., De Vos, C., de Précigout, V., Larroumet, N., et al. (1995) Clinical Evaluation of an Optimized 1.1% Amino-Acid Solution for Peritoneal Dialysis. Nephrology Dialysis Transplantation, 10, 1432-1437. [Google Scholar] [CrossRef] 
[8] Jones, M., Hagen, T., Boyle, C., Vonesh, E., Hamburger, R., Charytan, C., et al. (1998) Treatment of Malnutrition with 1.1% Amino Acid Peritoneal Dialysis Solution: Results of a Multicenter Outpatient Study. American Journal of Kidney Diseases, 32, 761-769. [Google Scholar] [CrossRef] [PubMed]
[9] Taylor, G.S., Patel, V., Spencer, S., Fluck, R.J. and McIntyre, C.W. (2002) Long-Term Use of 1.1% Amino Acid Dialysis Solution in Hypoalbuminemic Continuous Ambulatory Peritoneal Dialysis Patients. Clinical Nephrology, 58, 445-450. [Google Scholar] [CrossRef] [PubMed]
[10] Hsiung, J., Kleine, C., Naderi, N., Park, C., Soohoo, M., Moradi, H., et al. (2019) Association of Pre-End-Stage Renal Disease Serum Albumin with Post-End-Stage Renal Disease Outcomes among Patients Transitioning to Dialysis. Journal of Renal Nutrition, 29, 310-321. [Google Scholar] [CrossRef] [PubMed]
[11] Chan, W. (2021) Chronic Kidney Disease and Nutrition Support. Nutrition in Clinical Practice, 36, 312-330. [Google Scholar] [CrossRef] [PubMed]
[12] Park, M.S., Choi, S.R., Song, Y.S., Yoon, S.Y., Lee, S.Y. and Han, D.S. (2006) New Insight of Amino Acid-Based Dialysis Solutions. Kidney International, 70, S110-S114. [Google Scholar] [CrossRef] [PubMed]
[13] Stegmayr, B. (2017) Dialysis Procedures Alter Metabolic Conditions. Nutrients, 9, Article No. 548. [Google Scholar] [CrossRef] [PubMed]
[14] Li, F.K., Chan, L.Y.Y., Woo, J.C.Y., Ho, S.K.N., Lo, W.K., Lai, K.N., et al. (2003) A 3-Year, Prospective, Randomized, Controlled Study on Amino Acid Dialysate in Patients on CAPD. American Journal of Kidney Diseases, 42, 173-183. [Google Scholar] [CrossRef] [PubMed]
[15] Iyasere, O., Nagar, R., Jesus-Silva, J.A., Pepereke, S., MacConaill, K., Eid, A., et al. (2021) The Impact of Amino Acid Dialysate on Anthropometric Measures in Adult Patients on Peritoneal Dialysis: A Systematic Review and Meta-Analysis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 42, 314-323. [Google Scholar] [CrossRef] [PubMed]
[16] 刘红, 程铭, 姜琳, 等. 氨基酸腹膜透析对腹膜透析患者生化指标、透析效能及营养状况的影响[J]. 临床和实验医学杂志, 2020, 19(13): 1387-1390.
[17] 孙彬, 李雪芹, 马强. 氨基酸腹膜透析对腹膜透析患者透析效能和营养状况的影响[J]. 中国医药导刊, 2019, 21(1): 21-24.
[18] Kopple, J.D., Bernard, D., Messana, J., Swartz, R., Bergström, J., Lindholm, B., et al. (1995) Treatment of Malnourished CAPD Patients with an Amino Acid Based Dialysate. Kidney International, 47, 1148-1157. [Google Scholar] [CrossRef] [PubMed]
[19] Misra, M., Reaveley, D.A., Ashworth, J., Muller, B., Seed, M. and Brown, E.A. (1997) Six-Month Prospective Cross-Over Study to Determine the Effects of 1.1% Amino Acid Dialysate on Lipid Metabolism in Patients on Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 17, 279-286. [Google Scholar] [CrossRef] 
[20] Ikizler, T.A., Burrowes, J.D., Byham-Gray, L.D., Campbell, K.L., Carrero, J., Chan, W., et al. (2020) KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. American Journal of Kidney Diseases, 76, S1-S107. [Google Scholar] [CrossRef] [PubMed]
[21] ter Wee, P.M. and van Ittersum, F.J. (2007) The New Peritoneal Dialysis Solutions: Friends Only, or Foes in Part? Nature Clinical Practice Nephrology, 3, 604-612. [Google Scholar] [CrossRef] [PubMed]
[22] Li, P.K.T., Culleton, B.F., Ariza, A., Do, J., Johnson, D.W., Sanabria, M., et al. (2013) Randomized, Controlled Trial of Glucose-Sparing Peritoneal Dialysis in Diabetic Patients. Journal of the American Society of Nephrology, 24, 1889-1900. [Google Scholar] [CrossRef] [PubMed]
[23] Bonomini, M., Zammit, V., Divino-Filho, J.C., Davies, S.J., Di Liberato, L., Arduini, A., et al. (2020) The Osmo-Metabolic Approach: A Novel and Tantalizing Glucose-Sparing Strategy in Peritoneal Dialysis. Journal of Nephrology, 34, 503-519. [Google Scholar] [CrossRef] [PubMed]
[24] Jagirdar, R.M., Pitaraki, E., Rouka, E., Papazoglou, E.D., Bartosova, M., Zebekakis, P., et al. (2023) Differential Effects of Biocompatible Peritoneal Dialysis Fluids on Human Mesothelial and Endothelial Cells in 2d and 3d Phenotypes. Artificial Organs, 48, 484-494. [Google Scholar] [CrossRef] [PubMed]
[25] Kumar, P.S., Mauriello, C.T., Hair, P.S., Rister, N.S., Lawrence, C., Raafat, R.H., et al. (2015) Glucose-Based Dialysis Fluids Inhibit Innate Defense against Staphylococcus Aureus. Molecular Immunology, 67, 575-583. [Google Scholar] [CrossRef] [PubMed]
[26] Tobudic, S., Harrison, N., Forstner, C., Kussman, M. and Burgmann, H. (2017) Effect of Peritoneal Dialysis Fluids on Activity of Echinocandins against Candida Spp. Biofilm. Medical Mycology, 55, 790-793. [Google Scholar] [CrossRef] [PubMed]
[27] Tjiong, H.L., Swart, R., van den Berg, J.W. and Fieren, M.W. (2009) Amino Acid-Based Peritoneal Dialysis Solutions for Malnutrition: New Perspectives. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 29, 384-393. [Google Scholar] [CrossRef] 
[28] Kuok, M.C.I., Chow, C.K.J., Chan, N.M. and Chan, W.K.Y. (2025) Improvement of Lactic Acidosis in Pyruvate Dehydrogenase Complex Deficiency Using Custom-Made Amino Acid-Based Dialysate for Peritoneal Dialysis. Pediatric Nephrology, 40, 2201-2203. [Google Scholar] [CrossRef] [PubMed]
[29] Lui, S.L., Yung, S., Yim, A., Wong, K.M., Tong, K.L., Wong, K.S., et al. (2012) A Combination of Biocompatible Peritoneal Dialysis Solutions and Residual Renal Function, Peritoneal Transport, and Inflammation Markers: A Randomized Clinical Trial. American Journal of Kidney Diseases, 60, 966-975. [Google Scholar] [CrossRef] [PubMed]
[30] Yung, S., Lui, S.L., Ng, C.K.F., Yim, A., Ma, M.K.M., Lo, K.Y., et al. (2015) Impact of a Low-Glucose Peritoneal Dialysis Regimen on Fibrosis and Inflammation Biomarkers. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 35, 147-158. [Google Scholar] [CrossRef] [PubMed]
[31] Li, P.K.T., Dorval, M., Johnson, D.W., Rutherford, P., Shutov, E., Story, K., et al. (2015) The Benefit of a Glucose-Sparing PD Therapy on Glycemic Control Measured by Serum Fructosamine in Diabetic Patients in a Randomized, Controlled Trial (Impendia). Nephron, 129, 233-240. [Google Scholar] [CrossRef] [PubMed]
[32] Szeto, C.C. and Johnson, D.W. (2017) Low GDP Solution and Glucose-Sparing Strategies for Peritoneal Dialysis. Seminars in Nephrology, 37, 30-42. [Google Scholar] [CrossRef] [PubMed]
[33] Tjiong, H.L., Swart, R., Van den Berg, J.W. and Fieren, M.W. (2008) Dialysate as Food as an Option for Automated Peritoneal Dialysis. Clinical Kidney Journal, 1, iv36-iv40. [Google Scholar] [CrossRef] [PubMed]

为你推荐